Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Jennifer Kim downgraded Poseida Therapeutics (PSTX) to Neutral from Overweight without a price target after the company entered into a merger agreement to be acquired by Roche (RHHBY) at a price of $9.00 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones.